

RECEIVED

S02676/08

MAR 28 2003



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN REPLY APPLICATION OF

HANSON ET AL

SERIAL NUMBER: 09/996,345

FILED: 28 NOV 01

GROUP ART UNIT: 1621

EXAMINER: M.L. SHIPPEN

DATE: 13 MAR 03

TITLE: USE OF PROPARGYL GLYCINE AMINO PROPARGYL DIOL COMPOUNDS FOR TREATMENT OF RENAL FAILURE

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Commissioner of Patents and Trademarks,  
Washington D.C., 20231 on 13 MAR 03

J. Timothy Keane  
Registration No. 27,808

Date:

13 March 2003

**TERMINAL DISCLAIMER**

Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Sir:

I, J. Timothy Keane, represent that I am the attorney of record for this invention, that Pharmacia Corporation, parent company of G.D. Searle & Co., P.O. Box 5110, Chicago, Illinois 60680, a corporation in the State of Delaware, owns all of the right, title and interest in the above-identified application Serial No. 09/996,344, which is a divisional of Serial No. 09/479,280 filed January 6, 2000, which issued on January 29, 2002 as U.S. Patent No. 6,342,624, which is a continuation of application Serial No. 09/969,522 filed on November 3, 1997, which is now abandoned, which is a continuation of application Serial No. 08/771,334 filed January 16, 1996 which is now abandoned, which is a continuation of 08/586,440, filed January 16, 1996, which is now abandoned, which is a continuation of application Serial No. 08/199,237 filed February 28, 1994, now U.S. Patent No. 5,484,812, which is a continuation of 07/784,272, filed on October 29, 1991, now U.S. Patent No. 5,223,535.

09/96345

191025

04/17/2003 MURRAY 00000001

110.00 CH

01 FC:1814

Your petitioner, J. Timothy Keane, hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 for U.S. Patent No. 6,342,624, and hereby agrees enforceable only for and during such period that the legal title to such patent shall be the same as the legal title to U.S. Patent No. 6,342,624, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors and assigns.

In making the above disclaimer petitioner does not disclaim any terminal part of any patent granted on the above-identified application that would extend to the expiration date of the full or extended statutory term as defined in 35 U.S.C. 154 to 156 and 173 in the event that U.S. Patent No. 6,342,624 later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims canceled by a reexamination certificate, is reissued, or is otherwise terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

Further, the petitioner does not disclaim any right to extend the term of any patent issued for the above-identified application under 35 U.S.C. 156 from the date of expiration for such patent as is imposed by this terminal disclaimer.

The evidentiary documents accompanying or referred to in the Instant Terminal Disclaimer have been reviewed by the undersigned and it is certified that to the best of my knowledge and belief, title is in the assignee.

Signature

*J. Timothy Keane*  
J. Timothy Keane  
Attorney of Record  
Reg. No. 27,808  
Tel: 314-274-9090

Dated:

*13 March 2003*

PHARMACIA CORPORATION  
Global Patent Department  
P.O. Box 1027  
Chesterfield, MO 63006